-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-845 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYL-845 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYL-845 in Metastatic Melanoma Drug Details: LYL-845 is under development for the...
-
Product Insights
Neuromuscular Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromuscular Disorders - Drugs In Development, 2023’, provides an overview of the Neuromuscular Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromuscular Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) - Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Schizophrenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Schizophrenia - Drugs In Development, 2023’, provides an overview of the Schizophrenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-500 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-500 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-500 in Non-Small Cell Lung Cancer Drug Details: TAK-500...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bupivacaine in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bupivacaine in Post-Operative Pain report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bupivacaine in Post-Operative Pain Drug Details: Bupivacaine (ATX-101) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VRG-50635 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VRG-50635 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Livmoniplimab in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Livmoniplimab in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Livmoniplimab in Laryngeal Cancer Drug Details: Livmoniplimab (ABBV-151) is under development for...
-
Product Insights
RioCan – Verge Condos – Ontario
Equip yourself with the essential tools needed to make informed and profitable decisions with our RioCan - Verge Condos - Ontario report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the RioCan -...